The state cabinet of Odisha has approved a new Pharma & MedTech Policy designed to position the state as a competitive hub for pharmaceutical manufacturing, medical device production, and healthcare innovation.
The policy seeks to build a robust ecosystem for manufacturing and medical-technology firms, offering modern infrastructure, investor-friendly incentives, and streamlined regulatory approval to facilitate rapid scaling.
A central goal of the policy is the creation of dedicated industrial hubs and sector-specific clusters that will attract pharmaceutical companies, bulk-drug manufacturers, diagnostic device producers, and medical-technology innovators. These hubs and clusters are expected to form the backbone of a revitalised life sciences sector in the state.
The government plans to support investors via plug-and-play facilities, ready-to-use industrial land, and a package of incentives and regulatory facilitation. By doing so, the state aims to accelerate growth in domestic manufacturing capacity, strengthen supply chains, and open channels for future exports.
In addition to boosting manufacturing output, the policy is expected to generate high-skilled employment and foster collaborations between industry and academia, particularly in pharmaceuticals and medical-technology domains. The policy framework aims to encourage research, innovation and technology upgrades, thereby enhancing the quality and competitiveness of Odisha’s life-sciences ecosystem.
Implementation of the policy will be overseen by a newly established institutional mechanism, which will coordinate development work across planned industrial zones and engage with prospective domestic and international manufacturers.
With the policy now in place, authorities are likely to begin outreach efforts rapidly to attract companies looking to set up manufacturing and research installations.
